Redmile Group, LLC Buys Sarepta Therapeutics Inc, Tricida Inc, Centene Corp, Sells InflaRx NV, Array BioPharma Inc, Teva Pharmaceutical Industries

• New Purchases: SRPT, CNC, STOK, DXCM, AKRO, ADPT, PSNL, GTHX, BMRN, PRNB, AVDR, FTSV, AMED, HZNP, NBIX,
• Added Positions: TCDA, FOLD, KRYS, QURE, ALLK, TNDM, SYRS, SRRK, DCPH, EPZM, ODT, GRTS, BOLD, AXNX, ARGX, ANAB, BMY, ATRA, UNH, CELG, IMGN, ANTM, CBAY, TDOC, GBT, EIDX,
• Reduced Positions: ARRY, XNCR, CLVS, NVTA, EHTH, WMGI, LIVN, JAZZ, WVE, MOR, OXFD, ESTA, RGNX, BGNE,
• Sold Out: IFRX, TEVA, PEN, ALGN, BIIB, HSKA, PRAH, ICUI, ATRC, ARVN, AUPH, CI, GWPH, SAGE, SGRY, ACRS,

For the details of Redmile Group, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/redmile+group%2C+llc/current-portfolio/portfolio

1. Array BioPharma Inc (ARRY) - 8,752,254 shares, 12.04% of the total portfolio. Shares reduced by 20.22%
2. Amicus Therapeutics Inc (FOLD) - 22,792,634 shares, 8.45% of the total portfolio. Shares added by 16.19%
3. Fate Therapeutics Inc (FATE) - 10,359,666 shares, 6.24% of the total portfolio.
4. argenx SE (ARGX) - 1,068,832 shares, 4.49% of the total portfolio. Shares added by 4.88%
5. uniQure NV (QURE) - 1,669,525 shares, 3.87% of the total portfolio. Shares added by 27.69%

Redmile Group, LLC initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $112.21 and $151.95, with an estimated average price of $121.45. The stock is now traded at around $102.07. The impact to a portfolio due to this purchase was 1.86%. The holding were 412,000 shares as of .

Redmile Group, LLC initiated holding in Centene Corp. The purchase prices were between $47.01 and $57.88, with an estimated average price of $53.96. The stock is now traded at around $46.54. The impact to a portfolio due to this purchase was 1.08%. The holding were 690,870 shares as of .

Redmile Group, LLC initiated holding in Stoke Therapeutics Inc. The purchase prices were between $25.53 and $29.17, with an estimated average price of $26.85. The stock is now traded at around $32.63. The impact to a portfolio due to this purchase was 0.88%. The holding were 1,021,808 shares as of .

Redmile Group, LLC initiated holding in DexCom Inc. The purchase prices were between $111.38 and $155.66, with an estimated average price of $125.45. The stock is now traded at around $168.28. The impact to a portfolio due to this purchase was 0.77%. The holding were 172,100 shares as of .

Redmile Group, LLC initiated holding in Akero Therapeutics Inc. The purchase prices were between $18.08 and $19.83, with an estimated average price of $18.95. The stock is now traded at around $27.52. The impact to a portfolio due to this purchase was 0.66%. The holding were 1,168,802 shares as of .

Redmile Group, LLC initiated holding in Adaptive Biotechnologies Corp. The purchase prices were between $40.3 and $48.3, with an estimated average price of $44.3. The stock is now traded at around $45.04. The impact to a portfolio due to this purchase was 0.61%. The holding were 425,000 shares as of .

Redmile Group, LLC added to a holding in Tricida Inc by 296.74%. The purchase prices were between $31.16 and $39.46, with an estimated average price of $35.14. The stock is now traded at around $34.24. The impact to a portfolio due to this purchase was 1.71%. The holding were 1,945,200 shares as of .

Redmile Group, LLC added to a holding in Krystal Biotech Inc by 232.91%. The purchase prices were between $27.2 and $41.2, with an estimated average price of $32.66. The stock is now traded at around $44.01. The impact to a portfolio due to this purchase was 0.9%. The holding were 1,080,300 shares as of .

Redmile Group, LLC added to a holding in uniQure NV by 27.69%. The purchase prices were between $52.76 and $82.19, with an estimated average price of $63.55. The stock is now traded at around $56.38. The impact to a portfolio due to this purchase was 0.84%. The holding were 1,669,525 shares as of .

Redmile Group, LLC added to a holding in Allakos Inc by 25.40%. The purchase prices were between $36 and $44.73, with an estimated average price of $41.03. The stock is now traded at around $88.00. The impact to a portfolio due to this purchase was 0.6%. The holding were 2,300,301 shares as of .

Redmile Group, LLC added to a holding in Tandem Diabetes Care Inc by 36.23%. The purchase prices were between $54.41 and $71.7, with an estimated average price of $64.4. The stock is now traded at around $61.31. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,166,032 shares as of .

Redmile Group, LLC added to a holding in Syros Pharmaceuticals Inc by 120.06%. The purchase prices were between $5.5 and $9.75, with an estimated average price of $6.96. The stock is now traded at around $10.98. The impact to a portfolio due to this purchase was 0.55%. The holding were 3,620,376 shares as of .

Redmile Group, LLC sold out a holding in InflaRx NV. The sale prices were between $3.06 and $51.61, with an estimated average price of $31.98.

Redmile Group, LLC sold out a holding in Teva Pharmaceutical Industries Ltd. The sale prices were between $8.12 and $15.72, with an estimated average price of $12.08.

Redmile Group, LLC sold out a holding in Penumbra Inc. The sale prices were between $124.65 and $167.39, with an estimated average price of $144.09.

Redmile Group, LLC sold out a holding in Align Technology Inc. The sale prices were between $268.08 and $331.08, with an estimated average price of $301.8.

Redmile Group, LLC sold out a holding in Biogen Inc. The sale prices were between $219.29 and $241.72, with an estimated average price of $230.78.

Redmile Group, LLC sold out a holding in Heska Corp. The sale prices were between $70.1 and $85.17, with an estimated average price of $77.85.